Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting

International Journal of Infectious Diseases

Volumn 13, Issue 6, 2009, Pages

  Kumarasamy, N ^a   Venkatesh, Kartik K ^b   Devaleenol, Bella ^a   Saghayam, Suneeta ^a   Manohar, Deepak ^a   Poongulali, S ^a   Yepthomi, Tokugha ^a   Ambrose, Pradeep ^a   Solomon, Suniti ^a   Mayer, Kenneth H ^b  

^a YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^b BROWN UNIVERSITY   (United States)

Author keywords

Anemia; AZT; d4T; HAART; HIV; India; Resource limited settings

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; HEMOGLOBIN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; AGED; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIAN; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; TERTIARY HEALTH CARE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANEMIA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; INDIA; POVERTY; STAVUDINE; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 70350566621     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2008.11.030     Document Type: Article

References (16)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision). Available at: www.who.int/hiv/pub/guidelines/adult/en/index.html (accessed January 2009).
2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1 (accessed January 2009).
3. Kumarasamy N., Vallabhaneni S., Cecelia A.J., Yepthomi T., Balakrishnan P., Saghayam S., et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 41 (2006) 53-58
4. Huffam S., Srasuebkul P., Zhou J., Calmy A., Saphonn V., Kaldor J.M., et al., on behalf of the TREAT Asia HIV Observational Database (TAHOD). Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med 8 (2007) 465-471
5. Kumarasamy N., Venkatesh K.K., Cecelia A.J., Devaleenal B., Lai A.R., Saghayam S., et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS 22 (2008) 337-344
6. Curkendall S., Richardson J.T., Emons M.F., Fisher A.E., and Everhard F. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 8 (2007) 483-490
7. Rogers M., Gopalakrishnan G., Kumarasamy N., Flanigan T.P., Carpenter C.C., Mayer K.H., et al. HIV in couples in South India: implications for prevention. Int J STD AIDS 16 (2005) 442-445
8. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents, and adults in resource-limited settings: recommendations for a public health approach. Available at: http://www.who.int/hiv/pub/guidelines/ctx/en/index.html (accessed January 2009).
9. Benson C, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. University of Colorado Health Sciences Center; Centers for Disease Control and Prevention; National Institutes of Health; University of Washington; 2005.
10. Semba R., Shah N., Klein R.S., Mayer K.H., Schuman P., Vlahov D., and Human Immunodeficiency Virus Epidemiology Research Study Group. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 34 (2002) 260-266
11. Semba R., Shah N., Klein R.S., Mayer K.H., Schuman P., Gardner L.I., et al., HER (Human Immunodeficiency Virus Epidemiology Research) Study Gr*oup. Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. AIDS Patient Care STDS 15 (2001) 473-480
12. O'Brien M., Kupka R., Msamanga G.I., Saathoff E., Hunter D.J., and Fawzi W.W. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 40 (2005) 219-225
13. Kumarasamy N., Solomon S., Flanigan T.P., Hemalatha R., Thyagarajan S.P., and Mayer K.H. Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis 36 (2003) 79-85
14. Kumarasamy N., Solomon S., Chaguturu S.K., Cecelia A.J., Vallabhaneni S., Flanigan T.P., et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis 41 (2005) 1525-1528
15. Kumarasamy N., Venkatesh K.K., Cecelia A.J., Devaleenol B., Saghayam S., Yepthomi T., et al. Gender-based differences in treatment and outcome among HIV patients in South India. J Womens Health (Larchmt) 17 (2008) 1471-1475
16. Belperio P., and Rhew D.C. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 116 (2004) S27-43